SRZN

+ Watchlist + Portfolio

Surrozen, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $24.01
52-Week Range: $10.73 – $35.00
Market Cap: $276.21M
P/E (TTM): —
EPS (TTM): -40.06
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -25.39%
Gross Margin: -200.38%
Operating Margin: -207.40%
Profit Margin: 0.00%
Current Ratio: 12.14
Debt/Equity: —
Total Debt: $6.32M
Free Cash Flow: $-21.75M
Revenue Growth: 408.60%
Earnings Growth: —
Enterprise Value: $180.49M

SRZN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$12.50M	$0.00	$10.65M	$3.48M
Research & Development	$37.01M	$27.23M	$21.13M	$29.36M
Selling, General & Admin	$19.83M	$15.80M	$15.06M	$16.20M
Operating Expenses	$56.84M	$43.03M	$36.19M	$45.57M
Operating Income	-$44.34M	-$43.03M	-$25.54M	-$42.09M
EBITDA	-$42.38M	-$41.12M	-$24.10M	-$41.55M
Pretax Income	-$36.00M	-$43.04M	-$63.56M	-$242.03M
Net Income	-$36.00M	-$43.04M	-$63.56M	-$242.03M
Diluted EPS	-15.60	-21.33	-21.67	-32.37
Diluted Shares	2.31M	2.02M	2.93M	7.48M

SRZN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$24.69M	$36.04M	$34.56M	$89.25M
Receivables	$1.98M	$2.15M	$2.54M	$208.00K
Current Assets	$81.31M	$41.13M	$38.93M	$91.56M
Total Assets	$89.44M	$46.08M	$48.47M	$98.73M
Current Liabilities	$9.73M	$7.15M	$7.32M	$9.93M
Total Debt	$5.60M	$3.38M	$8.47M	$6.64M
Total Liabilities	$13.43M	$8.14M	$69.85M	$286.49M
Retained Earnings	-$178.65M	-$221.69M	-$285.26M	-$527.28M
Shareholders' Equity	$76.00M	$37.94M	-$21.38M	-$187.76M
Working Capital	$71.57M	$33.98M	$31.62M	$81.63M

SRZN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$44.15M	-$40.36M	-$17.63M	-$30.24M
Capital Expenditure	-$728.00K	-$398.00K	-$26.00K	-$128.00K
Free Cash Flow	-$44.87M	-$40.76M	-$17.65M	-$30.37M
Depreciation & Amortisation	$1.96M	$1.91M	$1.44M	$537.00K
Stock-Based Compensation	$4.52M	$4.37M	$4.11M	$3.83M
Investing Cash Flow	$38.31M	$51.72M	-$26.00K	-$128.00K
Financing Cash Flow	-$2.56M	$276.00K	$16.18M	$85.05M
Share Repurchases	-$2.61M	-$4.00K	$0.00	—
Net Change in Cash	-$8.40M	$11.64M	-$1.48M	$54.68M

SRZN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$983.00K	$983.00K	$983.00K	$528.00K	$5.00M
Research & Development	$6.56M	$6.04M	$7.77M	$8.99M	$9.33M
Selling, General & Admin	$3.98M	$3.96M	$4.09M	$4.18M	$6.13M
Operating Expenses	$10.53M	$10.00M	$11.87M	$13.17M	$15.46M
Operating Income	-$9.55M	-$9.02M	-$10.88M	-$12.64M	-$10.46M
EBITDA	-$9.26M	-$8.88M	-$10.82M	-$12.59M	-$10.39M
Pretax Income	-$26.97M	$39.75M	-$71.64M	-$183.16M	-$127.50M
Net Income	-$26.97M	$39.75M	-$71.64M	-$183.16M	-$127.50M
Diluted EPS	-7.43	2.55	-8.36	—	-11.65
Diluted Shares	3.63M	8.54M	8.57M	—	10.95M

SRZN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$101.64M	$90.39M	$81.33M	$89.25M	$106.91M
Receivables	$2.63M	$2.57M	$2.57M	$208.00K	$5.00M
Current Assets	$106.01M	$94.23M	$85.86M	$91.56M	$113.95M
Total Assets	$114.83M	$102.70M	$94.05M	$98.73M	$120.71M
Current Liabilities	$10.58M	$5.74M	$6.53M	$9.93M	$9.56M
Total Debt	$7.97M	$7.51M	$7.08M	$6.64M	$6.78M
Total Liabilities	$109.16M	$55.58M	$117.56M	$286.49M	$398.86M
Retained Earnings	-$312.23M	-$272.48M	-$344.13M	-$527.28M	-$654.79M
Shareholders' Equity	$5.67M	$47.11M	-$23.52M	-$187.76M	-$278.15M
Working Capital	$95.43M	$88.49M	$79.33M	$81.63M	$104.38M

SRZN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$9.28M	-$6.11M	-$9.04M	-$5.81M	-$12.49M
Capital Expenditure	-$27.00K	-$18.00K	-$24.00K	-$59.00K	-$120.00K
Free Cash Flow	-$9.31M	-$6.13M	-$9.06M	-$5.87M	-$12.62M
Depreciation & Amortisation	$294.00K	$137.00K	$61.00K	$45.00K	$65.00K
Stock-Based Compensation	$834.00K	$994.00K	$1.00M	$1.00M	$2.10M
Investing Cash Flow	-$27.00K	-$18.00K	-$24.00K	-$59.00K	-$120.00K
Financing Cash Flow	$76.39M	-$5.12M	$9.00K	$13.78M	$30.28M
Net Change in Cash	$67.08M	-$11.26M	-$9.05M	$7.91M	$17.66M

Market Snapshot

About

Surrozen, Inc. is a clinical-stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The companys antibody-based therapeutics target tissue-specific disease processes across multiple organs including the eye, liver, intestine, and kidney. It aims to address diseases where Wnt pathway dysregulation plays a critical role.